believe the increased sTfR concentration during pregnancy reflects increased erythropoietic activity in this period.
Assay for Free and Total Carnitine in Human Plasma
Measurements of free and total carnitine in plasma are important in the diagnosis and clinical management of patients with carnitine deficiency syndromes and certain inborn errors of metabolism (1 ) . The most popular analytical methods are based on the enzymatic reaction in which an acetyl group is transferred from acetyl-CoA to carnitine with release of free CoA (2 ) . A spectrophotometric assay based on this method, using a Cobas centrifugal analyzer (Roche Diagnostics), has been in use in this laboratory for the past several years (3 ) . Limitations of the Cobas enzymatic method in our view include the initial filtration step, which requires a minimum sample volume of 300 L, and the number and cost of the reagents required. Assay results are critically dependent on two labile reagents, the enzyme carnitine acetyltransferase and the color reagent 5,5Ј-dithiobis(2-nitrobenzoic acid). We have also observed that patients on valproic acid therapy sometimes give total carnitine values that are spuriously low for reasons that are not clear. Another limitation of the Cobas assay is that acylcarnitines with chain lengths Ͼ10 are lost in the filtration step (3 ), and the method will underestimate the total carnitine content of patients with defects in the oxidative degradation of longchain or multiple acyl-CoAs, especially when metabolically decompensated. We have emphasized previously that the most valuable applications of the routine Cobas assay are the identification of patients with carnitine deficiency and the monitoring of patients on carnitine therapy (3 ) .
We have developed a new carnitine assay method based on isotope-dilution tandem mass spectrometry (TMS), which is inherently more straightforward and accurate than previously reported methods. This is true primarily because it has absolute molecular specificity, uses an isotope-labeled internal standard to compensate for any losses or variance resulting from the sample preparation, and has no known chemical interference. The new assay procedure has been developed using a total specimen volume of 150 L, but it can easily be scaled down to much smaller volumes. A fixed amount of stable-isotope-labeled free carnitine is added, and one aliquot of the mixture is used directly for the free carnitine assay. Another aliquot is subjected to base-catalyzed hydrolysis before measurement of total carnitine. The analyte is not subjected to acid-catalyzed esterification, thus avoiding any inaccuracies in free carnitine measurement from the hydrolysis of acylcarnitines or incomplete derivatization. The specimen can be either serum or plasma, and any anticoagulant can be used. In this report, the specimens from patients were predominantly heparinized plasma (green-topped tubes).
To the unfiltered specimen (150 L), we added 30 L of a 250 mol/L solution of the internal standard, 2 H 3 -lcarnitine (Cambridge Isotope Laboratories). After vortex mixing, 50 L of the mixture was applied to a 6-mm disk of cotton fiber filter paper (no. 900; 1.88 mm thick; Schleicher & Schuell) placed in a well of a 96-well microtiter plate. The remaining mixture was hydrolyzed by the addition of 10 L of 1 mol/L KOH and incubation at 65°C for 15 min, and then neutralized by the addition of 10 L of 1 mol/L HCl. The mixture was centrifuged, and an aliquot of the supernate (50 L) was applied to a disk of cotton fiber placed in a well of a second microtiter plate as described. The specimens were air-dried in an oven at 40°C for 30 min, cooled to ambient temperature, and then extracted with 200 L of a mixture of methanol, water, and 6 mol/L HCl (400:100:0.5, by volume). After 20 min on an orbital shaker, ϳ100 L of extract was transferred to the adjacent well of the next row and was diluted with an additional 100 L of the acidified methanol/water mixture. Up to 48 samples were processed for either free or total carnitine on a single microtiter plate. The microtiter plates were sealed with a thin sheet of aluminum foil (Fisher Scientific) to limit solvent evaporation before analysis.
Aliquots of the samples (20 L) were injected directly into the electrospray ion source of a tandem mass spec-
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trometer (Quattro-LC; Micromass) equipped with a Hewlett-Packard HP1100 LC pump and Gilson model 215 sample handler fitted with the Gilson 701H microtiter plate rack. The pump was programmed to deliver solvent (methanol/water, 80:20, by volume) at 75 L/min, and there was no chromatographic column or filter between the injector and ion source. Data were acquired using a precursor ion scan of m/z 85 product ions over the range m/z 160 -210. The spectra were acquired in the multichannel acquisition mode with a scan time of 1 s at a collision cell argon pressure of 0.22 Pa. During the acquisition, the flow rate was reduced to 30 L/min. Under these conditions, each sample analysis took ϳ2.0 min, and the procedure for analyzing up to 10 microtiter plates can be fully automated. The extended scan range was adopted as a quality-control (QC) measure to monitor for the absence of the acetylcarnitine signal at m/z 204 in the hydrolyzed samples. Plasma concentrations were calculated using the ratio of signals of carnitine to its internal standard (m/z 162 and 165, respectively). A calibration curve was constructed from a series of calibrators of carnitine (7.5-120.0 mol/L) in normal human plasma (Biocell Laboratories).
Control experiments using isotope-labeled acetylcarnitine demonstrated that no hydrolysis of acylcarnitines occurred during sample preparation for the free carnitine measurement. Partial hydrolysis of acylcarnitines is known to occur during acid-catalyzed esterification (4 ), a procedure originally developed to enhance the sensitivity of free carnitine and acylcarnitines to TMS using the fast ion bombardment method of ionization (5 ) . Partial hydrolysis of shortchain acylcarnitines has also been observed during the heat-assisted evaporation of sample extracts before analysis (data not shown). The simplified procedure for sample preparation described here avoids these problems, assuring greater accuracy for free carnitine measurement.
The within-day and between-day results for replicate analyses of calibrators are summarized in Table 1 . These values are well within accepted limits. Daily QC was assessed by the analysis of bovine adult serum (Sigma) as a low value QC sample and bovine adult serum to which known amounts of free and octanoylcarnitine were added as a high value QC. A previously analyzed patient sample served as a "patient" QC. The results accumulated over a 3-month period are summarized as follows. For the low QC, free carnitine was 12.0 Ϯ 0.9 mol/L and total carnitine was 20.0 Ϯ 1.0 mol/L (n ϭ 27); for the high QC, free carnitine was 65 Ϯ 3 mol/L and total carnitine was 88 Ϯ 4 mol/L (n ϭ 27). The patient QC values replicated to within 5% on consecutive assays. These results are a major improvement over the values measured by the Cobas method, which had CVs that typically ranged from ϳ10% to 22% for QC samples, and inspire confidence in both the accuracy and precision of the TMS-based assay. The analysis by TMS of a pooled human plasma subjected to diafiltration through a 0.2 m membrane (Biocell) and shown by enzymatic assay to be essentially carnitine free gave no measurable signal at the mass of free carnitine. This experiment demonstrated that there is no interfering endogenous plasma component. The high molecular specificity of TMS also precludes interference at the signal for free carnitine from drugs and dietary components. These and other advantages of TMS have been discussed in a recent report by Magera et al. (6 ) .
The results for 76 patient samples assayed by the Cobas spectrophotometric method were compared with those from the new TMS assay. There was good correlation between the two methods for both free and total carnitine determinations: free carnitine, y ϭ 1.04 ϩ 1.017x; S y͉x ϭ 3.49; r 2 ϭ 0.941; total carnitine, y ϭ 1.89ϩ 0.974x; S y͉x ϭ 4.77; r 2 ϭ 0.913. The data were also compared using the Bland-Altman approach (7 ) . The limits of agreement [mean difference (Cobas Ϫ TMS) Ϯ 2 SD of the difference] for free and total carnitine were 1.6 Ϯ 6.9 and 0.84 Ϯ 9.5 mol/L, respectively. Although these differences are not considered significant for the initial clinical evaluation of patients, we recommend this new TMS assay for laboratories with high sample throughput, such as ours, for monitoring patients on carnitine therapy, and for use in clinical trials, where the accuracy and precision of the assay must meet strict criteria. An additional benefit realized for our laboratory was a substantial reduction in operating costs. The average annual expenditure for reagents (enzyme and chemicals), filters ("centrifree"), rotors, and miscellaneous parts for the analyzer was $11 000 US for 2000 assays by the Cobas spectrophotometric method. The annual cost of consumables for the TMS method, i.e., solvent, filter paper, microtiter plates, internal standard, and gases was $750 US for a similar number of assays. In addition, transferring this assay to TMS allowed cancellation of a maintenance contract for the Cobas analyzer. It is not the purpose of this communication to advocate the TMS over the Cobas method on the basis of a rigorous cost analysis. Our labor and overhead costs for the two methods are similar, but the capital equipment expense is three times greater for the TMS. However, in a laboratory setting where TMS is used for several assays, as is the case in other laboratories (6 ) , it makes economic sense to consolidate to one platform that can perform multiple assays without operator intervention. We have extended this method to include measurements of acetyl carnitine (data not shown). In this case, a mixture of labeled carnitines are added to plasma, and concentrations are calculated from calibration curves for free, acetyl, and total carnitine. The measurement of free carnitine, total carnitine, and specific acylcarnitines by TMS without prior derivatization of the analytes is therefore now practicable.
